Back

Watch Compare

Inventiva S.A.

Data quality: 17%

Also listed as IVEVF OTC

IVA

Nasdaq Manufacturing Chemicals

$5.26

▼ $0.24 (-4.36%)

Mkt Cap: 1.14 B

Company Details · Pierre Broqua

CEO: Pierre Broqua Employees: 114 IPO: May 07, 2019 Website

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Price

$5.48

Mkt Cap

1.14 B

Day Range

—

52-Week Range

—

Volume

—

Open —

50D / 200D Avg

—

50D / 200D Avg

—

Quick Summary

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

N/A

ROICN/A

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current RatioN/A

Interest CoverageN/A

Valuation

P/E Ratio

N/A

P/B RatioN/A

EV/EBITDAN/A

Dividend YieldN/A

Price History

Peer Comparison

vs Manufacturing sector median (1364 peers)

Metric	Stock	Sector Median
P/E	—	-1.5
P/B	—	1.6
ROE %	—	-53.3
Net Margin %	—	-41.5
Rev Growth 5Y %	—	1.8
D/E	—	0.3

Analyst Price Target

13 analysts

Buy

Current

$5.26

+187.6%

Target

$15.13

$8.80

$13.00

$26.00

Forecast

Forward P/E -4.14

Forward EPS -$1.27

Est. Revenue 109.70 M

Earnings Estimates

Period	EPS Est.	Revenue Est.	Analysts
FY2027	-$1.27 -$3.43 – -$0.65	109.70 M	7
FY2026	-$0.82 -$0.92 – -$0.67	4.97 M	6

Period	EPS Est.	Revenue Est.	Analysts
2026 Q2	-$0.20 -$0.20 – -$0.20	5.20 M	1
2026 Q1	-$0.23 -$0.23 – -$0.23	0.0	1

Earnings Surprises

Last 1 quarter

Quarter	Est. EPS	Actual EPS	Surprise
Q42025	-$0.18	N/A	—

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	N/A
ROE	N/A	ROA	N/A
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	N/A
ROIC	N/A	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	N/A
Interest Coverage	N/A	Asset Turnover	N/A
Working Capital	N/A	Tangible Book Value	N/A
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	N/A	Forward P/E	N/A
P/B Ratio	N/A	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	N/A
Market Cap	1.14 B	Enterprise Value	N/A
Per Share
EPS (Diluted TTM)	N/A	Revenue / Share	N/A
FCF / Share	N/A	OCF / Share	N/A
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	N/A
SBC-Adj. FCF	N/A	Growth Momentum	N/A